These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 34673645

  • 1. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
    Wang Y, Yuan X, Yang M, Shen Z, Chen H, He X, Ma Y, Ding L.
    Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
    [Abstract] [Full Text] [Related]

  • 2. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
    Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C, Zhao M, Su W, Zhang Y, Zhong D, Wu J, Zhang C, An G, Hu X, Cheng G, Wang H, Li Y, He X, Liu J, Liang L, Ding L, Mao L, Zhang S.
    Clin Cancer Res; 2020 Jul 01; 26(13):3162-3171. PubMed ID: 32060099
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z, Yu X, Cai J, Shao L, Lin B, He C, Zhang B, Zhang Y.
    Zhongguo Fei Ai Za Zhi; 2013 Mar 01; 16(3):138-43. PubMed ID: 23514942
    [Abstract] [Full Text] [Related]

  • 4. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H, Liu R, Li S, Fang H, Wang Z, Huang S, Zhou J.
    Cell Biochem Biophys; 2014 Sep 01; 70(1):553-8. PubMed ID: 24777808
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S, Hu X, Wang Y, Li J, Zhou L, Hao X, Liu Y, Shi Y.
    Asia Pac J Clin Oncol; 2019 Jun 01; 15(3):166-171. PubMed ID: 30311393
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y, Wang J, Yu Z, Ge H, Zhang LW, Feng LX.
    Clin Transl Sci; 2021 May 01; 14(3):890-897. PubMed ID: 33382908
    [Abstract] [Full Text] [Related]

  • 7. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
    Jiang Z, Zhang J, Sun H, Wang C, Zhang Y, Li Y, Pan Z.
    Thorac Cancer; 2021 Sep 01; 12(17):2369-2374. PubMed ID: 34255422
    [Abstract] [Full Text] [Related]

  • 8. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y.
    Ann Oncol; 2017 Oct 01; 28(10):2443-2450. PubMed ID: 28945850
    [Abstract] [Full Text] [Related]

  • 9. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X, Han B, Gu A, Zhang Y, Jiao SC, Wang CL, He J, Jia X, Zhang L, Peng J, Wu M, Ying K, Wang J, Ma K, Zhang S, You C, Tan F, Wang Y, Ding L, Sun Y.
    Lung Cancer; 2014 Nov 01; 86(2):207-12. PubMed ID: 25261231
    [Abstract] [Full Text] [Related]

  • 10. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T, Liu Y, Zhou B, Hao S, Wang Z, Liang N, Liu J, Wang S.
    Indian J Cancer; 2017 Nov 06; 54(1):215-222. PubMed ID: 29199694
    [Abstract] [Full Text] [Related]

  • 12. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B.
    Lung Cancer; 2016 Jun 06; 96():87-92. PubMed ID: 27133756
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
    Qu J, Wang YN, Xu P, Xiang DX, Yang R, Wei W, Qu Q.
    Oncotarget; 2017 May 16; 8(20):33961-33971. PubMed ID: 28430623
    [Abstract] [Full Text] [Related]

  • 14. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
    Fan Y, Xu Y, Gong L, Fang L, Lu H, Qin J, Han N, Xie F, Qiu G, Huang Z.
    Sci Rep; 2017 Mar 23; 7():45193. PubMed ID: 28332624
    [Abstract] [Full Text] [Related]

  • 15. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
    Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y.
    Cancer Med; 2020 Jan 23; 9(1):12-18. PubMed ID: 31692291
    [Abstract] [Full Text] [Related]

  • 16. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.
    Zhongguo Fei Ai Za Zhi; 2012 May 23; 15(5):299-304. PubMed ID: 22613337
    [Abstract] [Full Text] [Related]

  • 17. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Okuda Y, Sato K, Sudo K, Hasegawa Y, Asano M, Miura H, Takeda M, Sano M, Watanabe H, Kobayashi H, Niioka T, Miura M, Ito H.
    Cancer Chemother Pharmacol; 2017 May 23; 79(5):1013-1020. PubMed ID: 28391354
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R, Hua L, Wenlong G, Shuanying Y.
    Oncotarget; 2016 Dec 27; 7(52):86902-86913. PubMed ID: 27893423
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 27; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of icotinib in advanced lung squamous cell carcinoma.
    Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M.
    Cancer Med; 2018 Sep 27; 7(9):4456-4466. PubMed ID: 30109777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.